Nykode Therapeutics A Stock

Nykode Therapeutics A Dividend 2025

Nykode Therapeutics A Dividend

0 USD

Nykode Therapeutics A Dividend yield

Ticker

NYKD.OL

ISIN

NO0010714785

WKN

A2PZ5J

How much dividend does Nykode Therapeutics A 2025 pay?

According to the latest status from January 2025, Nykode Therapeutics A paid a total of 0 USD per share in dividends within the last 12 months. With the current Nykode Therapeutics A price of 0.23 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Nykode Therapeutics A Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Nykode Therapeutics A Dividend Safe?

Nykode Therapeutics A has been increasing the dividend for 0 years.

Over the past 8 years, Nykode Therapeutics A has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Nykode Therapeutics A's Dividend Distributions

Nykode Therapeutics A’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Nykode Therapeutics A's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Nykode Therapeutics A's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Nykode Therapeutics A’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Nykode Therapeutics A Aktienanalyse

What does Nykode Therapeutics A do?

Vaccibody AS is a Norwegian biotechnology company that was founded in 2007. It is headquartered in Oslo and currently employs about 40 people. The company specializes in the development of individualized vaccines based on DNA-based technology. The idea for founding Vaccibody came about when the two founders, Agnete Fredriksen and Bjarne Bogen, were collaborating at the University of Oslo. They wanted to develop a method to personalize vaccines in order to increase their effectiveness and compatibility. Their discovery is based on the fact that T-cells play an important role in the immune system and can recognize specific target proteins produced by cancer cells or viruses. Vaccibody's business model is based on the development of individualized vaccines based on DNA-based technology. The company has several different areas, including cancer immunotherapy, infectious diseases, and personalized medicine. Vaccibody's vaccines can be used for various types of cancer, such as lung, breast, and prostate cancer. Vaccibody offers a range of products, including a vaccine against HPV (human papillomavirus) that is approved for women aged 9 to 45. This vaccine aims to reduce the risk of cervical cancer. Another product from Vaccibody is the prostate cancer vaccine VCD-001. This vaccine uses the antigen PSA (prostate-specific antigen), which occurs on the surface of prostate cancer cells, to stimulate the patient's immune system. Vaccibody is also working on the development of vaccines against COVID-19 and has already achieved initial positive results in preclinical studies. As part of its personalized medicine division, Vaccibody offers the DNA platform VACCIBODY®, which is used to manufacture individualized DNA vaccines. This technology allows the vaccine to be tailored specifically to the needs of each patient. Vaccibody has achieved many important milestones since its inception. In 2018, the company received a $12.5 million investment to further develop its cancer immunotherapy platform. In 2020, Vaccibody received an additional $43.5 million investment to advance the development of its COVID-19 vaccine. Overall, Vaccibody has the potential to change the way vaccines are developed and used. DNA-based technology offers many advantages over conventional vaccines, especially in personalized medicine. Vaccibody is working hard to further develop its technology and bring its products to market in order to improve the lives of people around the world. Nykode Therapeutics A is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Nykode Therapeutics A stock

How much dividend does Nykode Therapeutics A pay?

Over the past 12 months, Nykode Therapeutics A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nykode Therapeutics A is expected to pay a dividend of 0 USD.

What is the dividend yield of Nykode Therapeutics A?

The current dividend yield of Nykode Therapeutics A is .

When does Nykode Therapeutics A pay dividends?

Nykode Therapeutics A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nykode Therapeutics A?

Nykode Therapeutics A paid dividends every year for the past 0 years.

What is the dividend of Nykode Therapeutics A?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nykode Therapeutics A located?

Nykode Therapeutics A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nykode Therapeutics A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nykode Therapeutics A from 1/18/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/18/2025.

When did Nykode Therapeutics A pay the last dividend?

The last dividend was paid out on 1/18/2025.

What was the dividend of Nykode Therapeutics A in the year 2024?

In the year 2024, Nykode Therapeutics A distributed 0 USD as dividends.

In which currency does Nykode Therapeutics A pay out the dividend?

The dividends of Nykode Therapeutics A are distributed in USD.

Andere Kennzahlen von Nykode Therapeutics A

Our stock analysis for Nykode Therapeutics A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nykode Therapeutics A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.